HIV treatment: time to lean forward
The Lancet - "The Lancet (Oct 10, p 1420) stated that the new WHO antiretroviral therapy (ART) guidelines are based on trials that “showed promising, but modest, benefits for affected individuals, and for reducing HIV transmission following early treatment initiation”
The benefits are not modest. (...) We have more knowledge about HIV than any other pathogen; a 1-min HIV test; five classes of drugs that prevent illness, death, and transmission; the ability to measure viral load; several proven prevention interventions; a robust human rights-based community response; a trained workforce; a treatment cost that has been reduced by 100 times; and $20 billion of budget per year."